Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet (London, England), 395, 565, 10.1016/S0140-6736(20)30251-8 Xu, 2020, Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2, Eur. J. Nucl. Med. Mol. Imag. Han, 2020, Recent insights into 2019-nCoV: a brief but comprehensive review, J. Infect., S0163–4453 Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, J. Am. Med. Assoc., 10.1001/jama.2020.2648 Rothan, 2020, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J. Autoimmun., 102433, 10.1016/j.jaut.2020.102433 Chen, 2007, The immunobiology of SARS*, Annu. Rev. Immunol., 25, 443, 10.1146/annurev.immunol.25.022106.141706 Zheng, 2018, Lysosomal proteases are a determinant of coronavirus tropism, J. Virol., 92, e01504, 10.1128/JVI.01504-18 Gao, 2020, Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, 10.5582/bst.2020.01047 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., ciaa237, 10.1093/cid/ciaa237 Channappanavar, 2017, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin. Immunopathol., 39, 529, 10.1007/s00281-017-0629-x Yoshikawa, 2009, Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells, J. Virol., 83, 3039, 10.1128/JVI.01792-08 Le, 2018, FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, Oncol., 23, 943, 10.1634/theoncologist.2018-0028 Xu Xh, 2020 Yang, 2020, The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China, J. Autoimmun., 102434, 10.1016/j.jaut.2020.102434 Richardson, 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet (London, England), 395, e30, 10.1016/S0140-6736(20)30304-4 Channappanavar, 2016, Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice, Cell Host Microbe, 19, 181, 10.1016/j.chom.2016.01.007 Zheng, 2018, Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host, Curr. Opin. Virol., 28, 43, 10.1016/j.coviro.2017.11.002 Cameron, 2007, Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome, J. Virol., 81, 8692, 10.1128/JVI.00527-07 Vaine, 2014, The CD200-CD200R1 inhibitory signaling pathway: immune regulation and host-pathogen interactions, Adv. Immunol., 121, 191, 10.1016/B978-0-12-800100-4.00005-2 Karnam, 2012, CD200 receptor controls sex-specific TLR7 responses to viral infection, PLoS Pathog., 8, 10.1371/journal.ppat.1002710 Hayakawa, 2016, CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation, J. Cerebr. Blood Flow Metabol., 36, 781, 10.1177/0271678X15606148 Seeds, 2011, The role of myeloid receptors on murine plasmacytoid dendritic cells in induction of type I interferon, Int. Immunopharm., 11, 794, 10.1016/j.intimp.2011.01.013 Jani, 2019, Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?, Curr. Opin. Rheumatol., 31, 285, 10.1097/BOR.0000000000000598